Cambridge, UK, 4th November 2024: Spirea Limited, a biopharmaceutical company developing a new generation of antibody drug conjugate (ADC) cancer therapeutics, based on its unique multivalent ELIVATE linker technology, is delighted to announce the appointment of Dr Bo Rode Hansen as an Executive Director. Bo will lead Spirea to secure the company’s primary position in next-generation ADCs for cancer and beyond.
Bo is an accomplished executive in the life science industry who brings transformative leadership and strategic insight to Spirea, leveraging over two decades in general management, board roles, R&D, business development, and financing within the biotech and pharmaceutical sectors. His experience in driving growth through IPOs, M&As, and strategic partnerships at companies including Santaris Pharma, Roche, Genevant Sciences and Scandion Oncology will be invaluable in guiding Spirea’s expansion.
Bo holds an MSc in Biochemistry and a PhD in Pharmaceutical Sciences from the University of Copenhagen, and an MBA from Henley Business School.
“We are thrilled to welcome Bo to the company and are very much looking forward to benefiting from his experience, as we drive the development of next generation ADCs using our unique ELIVATE linker technology and progress our pipeline of innovative cancer therapeutics” said Dr Myriam Ouberai, Founder & Spirea’s Chief Scientific Officer.
Dr Jane Dancer, Chair of Spirea’s Board added: “Bo has an impressive track record in building successful life science businesses, we are delighted that he has agreed to join our board. As Executive Director he will lead Spirea, which is set to unlock the potential of ADCs in cancer and beyond through its unique multivalent ELIVATE linker technology”
About Spirea
Spirea is focused on fulfilling the full therapeutic potential of Antibody Drug Conjugates (ADCs) in cancer and beyond by using the company’s unique multivalent ELIVATE linker technology to significantly expand the accessible ADC payload repertoire and power the next generation of ADCs. With ELIVATE, Spirea can fully leverage and optimise the benefits of incorporating payloads with a broad variety of therapeutic modes-of-action to ensure that the optimal drug type is targeted to the correct cells at the optimum drug concentration. Spirea is progressing an exciting therapeutics pipeline and exemplifying the ELIVATE linker technology with proprietary and differentiated linker-payloads inhouse and in collaboration with our pharma partners. Our dedicated and experienced team is committed to generating significant shareholder value from its ELIVATE linker platform by greatly improving the patient outcomes that ADCs can deliver in cancer and beyond.